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In this issue of Diabetes Care, Selvin and
Ali (1) have done a masterful job of ex-
ploring and explaining both the rise in the
incidence of diabetes over 20 years and
the fall in the incidence of diabetes over
the last 5 years in the U.S. You may want
to skip this and just read their article. The
bottom line is that we as clinicians can
confirm that they, as epidemiologists,
have almost certainly gotten it right. Im-
portantly, their analysis has critical impli-
cations for policy makers.
There are a couple of critical definitions
that need to be clarified. First, the term
“incidence” refers to an annual rate of
new diagnoses. That is the feature of di-
abetes explored in this article and here
refers specifically to the number of peo-
ple who report in a survey that a health
care professional told them for the first
time that they had diabetes in the last
year. That number has dropped about
20% since 2009 (2). Incidence needs to
be distinguished from “prevalence,”
which refers to the number or proportion
affected by a condition. For diabetes, that
is a number that continues to rise and is
only peripherally addressed (3).
While clinicians tend to not focus on
research methodology, in this case the
methods are crucial to understand. The
data from which incidence rates are de-
rived is national survey data. These data
are the best we have. But as has become
clear in recent elections, surveys have in-
herent issues and are arguably more
challenging to administer and interpret
today than in the past (4). A positive re-
sponse in such a survey is the culmination
of many factors, each with secular
trendsda person responded to the sur-
vey, they understood the question, they
sawa health care provider in the last year,
the provider screened for diabetes, the
provider communicated the result of the
test appropriately, the patient under-
stood the communication, and the pa-
tient was willing to disclose the result
during the survey. At the base of that
pyramid of issues is the fact that people
are rapidly changing the way that they
communicate with others and different
segments of the population are changing
in different ways. The authors point out
that the observation is supported by data
from insured populations in data from
health systems and claims data, again
with inherent limitations, as there arema-
jor changes across the country and par-
ticularly in some communities in the
proportion and demographics of the pop-
ulation that is insured. Though we do be-
lieve that Selvin and Ali are correct, it
must be kept in mind that they base their
observations on imprecise data.
Selvin andAli’s focus is not really on the
rise and fall of the incidence of diabetes;
their article is an exploration of the rea-
sons for the trend and the implications of
their understanding. The story the au-
thors develop is compelling and worth
reflection. In the early 1990s, the rate of
newly diagnosed diabetes in the U.S.
began to rise sharply from about 4 per
1,000 person-years from 1980–1991 to
over 8 per 1,000 patient-years in 2008
with seemingly no end in sight (2). The
rate reported isageadjusted, so the increas-
ing age of the populationwas not contrib-
uting to the rise. Changing demography
and obesity rates certainly contributed to
the trend but obviously did not change
abruptly as seems the case for the inci-
dence of diabetes. Starting in 2009 and
continuing since, the incidence rate of di-
abetes seems to be falling; however,
biological factors cannotexplain this rapid
change.
As Selvin and Ali point out, important
nonbiological factors may explain much
of the rise and fall in incidence. First, in
1997 the American Diabetes Association
loosened the diagnostic criteria for diabe-
tes by lowering the fasting glucose cut
point from 140 mg/dL to 126 mg/dL. Sec-
ond, in 2010 the American Diabetes Asso-
ciation broadened the criteria to include
using glycated hemoglobin A1c (HbA1c) for
diagnosis. While the intent was to enable
the diagnosis of diabetes in the nonfast-
ing state, the HbA1c purposefully is amore
specific (fewer false positives) and less
sensitive (more false negatives) crite-
rion and has been widely adopted (5).
Third, along with the changing criteria
came increased efforts at screening for
diabetes. Over the last 30 years the pro-
portion of people with diabetes who are
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undiagnosed has decreased from over
50% to about 11%. This is a crucial under-
standing. Biology changes slowly, and al-
most certainly the story of both the
abrupt rise and fall in incidence of diabe-
tes is really a story of changing guidelines
and health policy.
The most important statement from
their article is “the war is not yet won.”
There is no inherent reason to celebrate
the decline in incidence seen in adults.
It is a victory of sorts, but the number of
people living with diabetes is staggering
and increasing. An alarmingly high and
increasing proportion of our nation’s
health care resources are expended in
the care of diabetes and its complications
and comorbidities. The burden of dia-
betes care not only impacts the quality
of life of hundreds of millions of people
globally but also stresses our health care
systems and as a result our society to
near the breaking point. Recent trends
examining the incidence of diabetes in
youth in the U.S. demonstrated signifi-
cant increases, particularly in racial and
ethnic groups other than non-Hispanic
whites (6). One can only imagine the
impact this will have on our health care
system. That said, we have almost cer-
tainly arrived at a time and place where
the ability to prevent diabetes and diag-
nose early and treat adequately allows
at least the socially and financially gifted
the ability to stave off diabetes-related
complications. The war is not won, but
the battle has changed from diagnosis
to population-wide implementation of
health policies to ensure cost-effective
efforts at preventiondprevention of
diabetes and prevention of diabetes
complications.
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